Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Molly Harper Sells 26,746 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 26,746 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the transaction, the director directly owned 2,360 shares in the company, valued at $54,870. This represents a 91.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Catalyst Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:CPRX traded up $0.01 during trading on Tuesday, hitting $24.19. 1,365,499 shares of the company traded hands, compared to its average volume of 1,358,966. The business’s fifty day moving average is $22.04 and its 200-day moving average is $21.60. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 0.84 and a beta of 0.68. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share for the quarter. The business had revenue of $53.11 million for the quarter. Catalyst Pharmaceuticals had a return on equity of 39.24% and a net margin of 37.63%. On average, analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current year.

Catalyst Pharmaceuticals declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 1st that permits the company to buyback $200.00 million in shares. This buyback authorization permits the biopharmaceutical company to buy up to 8.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Algert Global LLC boosted its stake in Catalyst Pharmaceuticals by 1.0% during the 1st quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company’s stock valued at $1,173,000 after purchasing an additional 470 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 498 shares during the period. Mission Wealth Management LP boosted its stake in Catalyst Pharmaceuticals by 5.0% during the second quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 510 shares in the last quarter. Hancock Whitney Corp boosted its stake in Catalyst Pharmaceuticals by 1.4% during the first quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company’s stock valued at $942,000 after buying an additional 525 shares in the last quarter. Finally, New York State Teachers Retirement System grew its holdings in Catalyst Pharmaceuticals by 0.4% during the second quarter. New York State Teachers Retirement System now owns 149,887 shares of the biopharmaceutical company’s stock worth $3,253,000 after acquiring an additional 577 shares during the period. Institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CPRX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Weiss Ratings raised Catalyst Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Citigroup raised their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $32.67.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.